Advertisement

CNS Drugs

, Volume 33, Issue 7, pp 685–694 | Cite as

Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study

  • Bruno AgustiniEmail author
  • Mohammadreza Mohebbi
  • Robyn L. Woods
  • John J. McNeil
  • Mark R. Nelson
  • Raj C. Shah
  • Anne M. Murray
  • Michael E. Ernst
  • Christopher M. Reid
  • Andrew Tonkin
  • Jessica E. Lockery
  • Michael Berk
  • the ASPREE Investigator Group
Original Research Article
  • 82 Downloads

Abstract

Background

Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling older adults living in Australia and the USA.

Methods

We analysed baseline data from 19,114 participants, over 70 years of age (over 65 years of age, if from an ethnic minority). The association of self-reported statin use and prevalence of depressive symptoms, as measured by a validated depression scale [Center for Epidemiological Studies Depression Scale (CES-D 10)], was determined using logistic regression models. Multivariable logistic models were implemented to account for important demographics and other lifestyle and socioeconomic factors, such as sex, age, living status, education and smoking history.

Results

A total of 5987 individuals were statin users. Of those, 633 (10.6%) had depressive symptoms (CES-D 10 cut-off ≥ 8), compared with 1246 (9.5%) of the non-statin users. In the unadjusted model, statin use was associated with an increase in prevalence of depressive symptoms (odds ratio 1.13, confidence interval 1.02–1.25, p = 0.02). However, after adjusting for important demographic and socioeconomic factors, the use of statins was not significantly associated with depressive symptoms (odds ratio 1.09, confidence interval 0.98–1.20, p = 0.11). In secondary analyses, only simvastatin was marginally associated with an increased prevalence of depressive symptoms. Statins were associated with a decreased prevalence of depressive symptoms in individuals with severe obesity (body mass index > 35 kg/m2) and an increased prevalence in participants between 75 and 84 years of age.

Conclusion

This study in a large community-dwelling older population did not show any association of statins with late-life depressive symptoms, after accounting for important socioeconomic and demographic factors. Confounding by indication is an important issue to be addressed in future pharmacoepidemiologic studies of statins.

Notes

Acknowledgements

The authors acknowledge the efforts of research personnel and the long-term involvement of participants of the ASPREE study.

Author Contributions

JJM, RLW, MRN, RCS, CMR and JEL contributed to the design of the original ASPREE randomised controlled trial. MB, RLW, MRN, RCS, CMR, AT, CB, JEL, MM and JJM contributed to the design of the ASPREE-D sub-study. All authors actively participated in designing the current study. BA and MM performed the data analysis. BA drafted the manuscript that has been read, edited and approved by all co-authors.

Compliance with Ethical Standards

Funding

The study is supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (Grant No. U01AG029824), the National Health and Medical Research Council of Australia (Grant Nos. 334047, 1127060), Monash University (Australia) and the Victorian Cancer Agency (Australia). Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (APP1059660 and APP1156072) and Christopher M. Reid is supported by a NHMRC Senior Research Fellowship (APP1045862).

Conflict of interest

Bruno Agustini, Mohammadreza Mohebbi, Robyn L. Woods, John J. McNeil, Mark R. Nelson, Raj C. Shah, Anne M. Murray, Michael E. Ernst, Christopher M. Reid, Andrew Tonkin, Jessica E. Lockery and Michael Berk have not conflicts of interest that are directly relevant to the content of this article.

Ethics approval

The ASPREE study was conducted in accordance with the Declaration of Helsinki 1964 as revised in 2008, the NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and the International Conference of Harmonisation Guidelines for Good Clinical Practice. ASPREE also follows the Code of Federal Regulations as it relates to areas of clinical research.

References

  1. 1.
    Arokiasamy P, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Med. 2015;13(1):1–16.CrossRefGoogle Scholar
  2. 2.
    World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. p. 1–24.Google Scholar
  3. 3.
    Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.CrossRefGoogle Scholar
  4. 4.
    Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology. 2015;144(3):365–73.CrossRefGoogle Scholar
  5. 5.
    You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother. 2013;14(11):1467–76.CrossRefGoogle Scholar
  6. 6.
    Williams LJ, et al. Statin and aspirin use and the risk of mood disorders among men. Int J Neuropsychopharmacol. 2016;19(6):1–4.Google Scholar
  7. 7.
    Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235–42.CrossRefGoogle Scholar
  8. 8.
    Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry. 2014;14:438.CrossRefGoogle Scholar
  9. 9.
    Mandas A, et al. Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. Neurol Res. 2014;36(3):247–54.CrossRefGoogle Scholar
  10. 10.
    Tuccori M, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs. 2014;28(3):249–72.CrossRefGoogle Scholar
  11. 11.
    Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.CrossRefGoogle Scholar
  12. 12.
    Dave CV, Winterstein AG, Park H, Cook RL, Hartzema AG. Comparative risk of lipophilic and hydrophilic statins on incident depression: a retrospective cohort study. J Affect Disord. 2018;238:542–6.CrossRefGoogle Scholar
  13. 13.
    Glaus J, et al. Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study. J Affect Disord. 2015;182:126–31.CrossRefGoogle Scholar
  14. 14.
    Bulbulia R, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013–20.CrossRefGoogle Scholar
  15. 15.
    Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.CrossRefGoogle Scholar
  16. 16.
    Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94.CrossRefGoogle Scholar
  17. 17.
    Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33–40.CrossRefGoogle Scholar
  18. 18.
    Waters DD. Meta-analyses of statin trials: clear benefit for primary prevention in the elderly. J Am Coll Cardiol. 2013;62(22):2100–1.CrossRefGoogle Scholar
  19. 19.
    Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572–4.CrossRefGoogle Scholar
  20. 20.
    McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379:1519–28.CrossRefGoogle Scholar
  21. 21.
    McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18.CrossRefGoogle Scholar
  22. 22.
    Grimm R, et al. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555–64.CrossRefGoogle Scholar
  23. 23.
    Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1993;10(2):77–84.CrossRefGoogle Scholar
  24. 24.
    Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis. PLoS One. 2016;11(5):1–17.CrossRefGoogle Scholar
  25. 25.
    Mohebbi M, et al. Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. Gen Hosp Psychiatry. 2018;51:118–25.CrossRefGoogle Scholar
  26. 26.
    Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult. Arch Intern Med. 1999;159:1701–4.CrossRefGoogle Scholar
  27. 27.
    Cheng ST, Chan ACM. The Center for Epidemiologic Studies Depression Scale in older Chinese: thresholds for long and short forms. Int J Geriatr Psychiatry. 2005;20(5):465–70.CrossRefGoogle Scholar
  28. 28.
    Alberti KGM, Zimmet P, Shaw J. The IDF consensus worldwide definition of the metabolic syndrome. Brussels Int Diabetes Fed. 2006;23(5):469–80.Google Scholar
  29. 29.
    Otte C, et al. Major depressive disorder. Nat Rev Dis Prim. 2016;2:16065.CrossRefGoogle Scholar
  30. 30.
    Delgado I, et al. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.CrossRefGoogle Scholar
  31. 31.
    Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28(11):1295–302.CrossRefGoogle Scholar
  32. 32.
    De Jonge P, Roy JF, Saz P, Marcos G, Lobo A. Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia. 2006;49(11):2627–33.CrossRefGoogle Scholar
  33. 33.
    Bagherniya M, et al. Metabolic syndrome and its components are related to psychological disorders: a population based study. Diabetes Metab Syndr Clin Res Rev. 2017;11:S561–6.CrossRefGoogle Scholar
  34. 34.
    Mulvahill JS, et al. Effect of metabolic syndrome on late-life depression: associations with disease severity and treatment resistance. J Am Geriatr Soc. 2017;65(12):2651–8.CrossRefGoogle Scholar
  35. 35.
    Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319(22):2289.CrossRefGoogle Scholar
  36. 36.
    Agustini B, Berk M. Medications with depression as an adverse effect. JAMA. 2018;320(17):1815.CrossRefGoogle Scholar
  37. 37.
    Friis RH, Sellers TA. Experimental study designs. Epidemiol Public Health Pract. 2009;275(6):327–60.Google Scholar
  38. 38.
    Köhler-Forsberg O, Gasse C, Petersen L, Nierenberg AA, Mors O, Østergaard SD. Statin treatment and the risk of depression. J Affect Disord. 2019;246:706–15.CrossRefGoogle Scholar
  39. 39.
    Mansi I, Frei CR, Pugh MJ, Mortensen EM. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy. 2013;33(6):615–26.CrossRefGoogle Scholar
  40. 40.
    Schaakxs R, Comijs HC, Lamers F, Kok RM, Beekman ATF, Penninx BWJH. Articles associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study. Lancet Psychiatry. 2018;366(18):1–10.Google Scholar
  41. 41.
    Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–74.CrossRefGoogle Scholar
  42. 42.
    Geerlings MI, Gerritsen L. Late-life depression, hippocampal volumes, and hypothalamic-pituitary-adrenal axis regulation: a systematic review and meta-analysis. Biol Psychiatry. 2017;82(5):339–50.CrossRefGoogle Scholar
  43. 43.
    Liang Feng TPN, Yap KB, Kua E. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf. 2010;19:942–8.CrossRefGoogle Scholar
  44. 44.
    Bornstein SR, Schuppenies A, Wong M-L, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Mol Psychiatry. 2006;11(10):892–902.CrossRefGoogle Scholar
  45. 45.
    Raison CL, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31–41.CrossRefGoogle Scholar
  46. 46.
    Köhler O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry. 2014;71(12):1381–91.CrossRefGoogle Scholar
  47. 47.
    McFarland AJ, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15(11):20607–37.CrossRefGoogle Scholar
  48. 48.
    Davison KM, Kaplan BJ. Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders. Crisis. 2014;35(4):278–82.CrossRefGoogle Scholar
  49. 49.
    Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis. 2016;58(5):514–28.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bruno Agustini
    • 1
    Email author
  • Mohammadreza Mohebbi
    • 1
    • 2
  • Robyn L. Woods
    • 3
  • John J. McNeil
    • 3
  • Mark R. Nelson
    • 4
  • Raj C. Shah
    • 5
  • Anne M. Murray
    • 6
  • Michael E. Ernst
    • 7
    • 8
  • Christopher M. Reid
    • 3
    • 9
  • Andrew Tonkin
    • 3
  • Jessica E. Lockery
    • 3
  • Michael Berk
    • 1
    • 10
  • the ASPREE Investigator Group
  1. 1.IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment Strategic Research Centre), School of MedicineDeakin UniversityGeelongAustralia
  2. 2.Biostatistics UnitDeakin UniversityGeelongAustralia
  3. 3.School of Public Health and Preventive MedicineMonash UniversityMelbourneAustralia
  4. 4.Menzies Institute for Medical ResearchUniversity of TasmaniaHobartAustralia
  5. 5.Department of Family Medicine and Rush Alzheimer’s Disease CenterRush University Medical CenterChicagoUSA
  6. 6.Berman Center for Outcomes and Clinical ResearchHennepin Healthcare Research Institute, Hennepin HealthcareMinneapolisUSA
  7. 7.Department of Pharmacy Practice and Science, College of PharmacyThe University of IowaIowaUSA
  8. 8.Department of Family Medicine, Carver College of MedicineThe University of IowaIowaUSA
  9. 9.School of Public HealthCurtin UniversityPerthAustralia
  10. 10.Orygen, National Centre of Excellence in Youth Health, Department of Psychiatry and the Florey Institute for Neuroscience and Mental HealthUniversity of MelbourneMelbourneAustralia

Personalised recommendations